Bone mineral density as a surrogate biomarker for fracture risk ...

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data

Bone mineral density as a surrogate biomarker for fracture risk reduction - Authors' reply.

Bone mineral density as a surrogate biomarker for fracture risk ...

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data.

Bone mineral density as a surrogate biomarker for fracture risk ...

Bone mineral density as a surrogate biomarker for fracture risk reduction ... Lancet Diabetes Endocrinol. 2020 Nov;8(11):875. doi: 10.1016/S2213-8587(20)30338-7.

Articles. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient ...

FDA Issues Timeline for Determination on FNIH-ASBMR-SABRE ...

Analysis of these data by the project team indicated a strong association between the treatment-related increase in bone mineral density, as ...

Validation of the Surrogate Threshold Effect for Change in Bone ...

In the field of osteoporosis, we have proposed that change in bone mineral density (BMD) of the total hip could be a surrogate outcome for fracture risk ...

ASBMR SABRE Team Submits Full Qualification Plan to FDA for ...

The study findings identified an increase in bone mineral density, as measured by a low-dose X-ray imaging technique, as a strong predictor of ...

FDA Approves Biomarker Qualification Plan for the First Surrogate ...

An increase in bone mineral density could therefore be used in future clinical trials to determine the effectiveness of osteoporosis drugs. The ...

analysis from the FNIH-ASBMR SABRE project | Journal of Bone ...

Compared to those with FN BMD T-score > −2.5, the risk reduction for each fracture outcome was greater in those with T-score ≤ −2.5, but only ...

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data ...

Bone mineral density as a surrogate biomarker for fracture risk ...

Bone mineral density as a surrogate biomarker for fracture risk reduction · October 2020 · The Lancet Diabetes & Endocrinology 8(11):875.

Bone mineral density as a surrogate biomarker for fracture risk ...

Bone mineral density as a surrogate biomarker for fracture risk reduction – Authors' reply ... We thank Viral Shah and Josivan Lima and colleagues for their ...

Bone mineral density as a surrogate biomarker for fracture risk ...

This is a comment on "Bone mineral density as a surrogate biomarker for fracture risk reduction." Lancet Diabetes Endocrinol. 2020 Nov;8(11):875 ...

Hip BMD changes explained substantial proportions (44–67%) of treatment-related fracture risk reduction. Interpretation Treatment-related BMD changes are ...

Is bone density a valid surrogate for fracture?

ship between fracture endpoints and surrogates such as bone mineral density (BMD) or bone turnover markers. Statistical methodology constitutes a critical ...

Biomarkers Consortium - Bone Quality Project - FNIH

Patients with osteoporosis, other bone diseases or increased risk for bone fractures have diminished bone strength and quality, yet researchers lack the tools ...

Operationalizing Treat-to-Target for Osteoporosis

Bone mineral density (BMD) is commonly used to select patients for treatment and has emerged as the most useful surrogate for assessing ...

Validation of the Surrogate Threshold Effect for Change in Bone ...

Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of ...

Study Finds BMD Can Stand in for Fractures. Will the FDA Agree?

MONTREAL, QUEBEC — Improvements in bone mineral density (BMD) after 2 years of osteoporosis drug therapy could serve as a surrogate ...